Baraclude

his medication may cause lactic acidosis (a build-up of lactic acid in the body, which can be fatal). Lactic acidosis can start slowly and get worse over time. Get emergency medical help if you have even mild symptoms of lactic acidosis, such as: muscle pain or weakness; numb or cold feeling in your arms and legs; trouble breathing; feeling dizzy, light-headed, tired, or very weak; stomach pain, nausea with vomiting; or slow or uneven heart rate. Entecavir may also cause severe liver symptoms. Call your doctor at once if you have any of these liver symptoms: low fever; nausea, stomach pain, loss of appetite; dark urine, clay-colored stools; or jaundice (yellowing of the skin or eyes). Less serious side effects may include: mild nausea, vomiting, diarrhea, upset stomach; temporary hair loss; headache; skin rash; or sleep problems (insomnia).

Baraclude is a guanosine nucleoside analogue with selective activity against hepatitis B virus (HBV). It is designed to selectively inhibit the Hepatitis B virus, blocking all three steps in the replication process. Baraclude is more efficient than an older Hepatitis B drug, lamivudine. Indication: For the treatment of chronic hepatitis B virus infection in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. Baraclude is an antiviral medicine. It is used to treat long-term hepatitis B virus infection of the liver. Baraclude decreases the amount of virus in your body and reduces further liver damage. However, it may not prevent hepatitis B complications such as liver cancer or end stage liver damage. It does not prevent the spread of hepatitis B to other people. Treatment of chronic HBV infection in adults with evidence of active liver inflammation. Treatment of chronic hepatitis B virus infection in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. This indication is based on histologic, virologic, biochemical and serologic responses after 1 year of treatment in nucleoside-treatment-naive and lamivudine-resistant adult patients with HBeAg-positive or HBeAg-negative chronic HBV infection with compensated liver disease and on more limited data in adult patients with HIV/HBV co-infection who have received prior lamivudine therapy. Indications: chronic hepatitis b Treatment of chronic HBV infection in adults w/ evidence of active viral replication & either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. Baraclude, an anti-retroviral drug, is prescribed for the treatment of chronic hepatitis B infections including compensated liver diseases and uncompensated liver diseases. The drug inhibits viral replication in hepatitis B infected patients. Indications: Anti-viral drug used in the treatment of hepatitis B infection (chronic hepatitis and hepatitis B infection with HIV infection). It is not effective against HIV infection.